)
Ultralife (ULBI) investor relations material
Ultralife Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q1 2026 revenue was $47.4 million, down 6.5% year-over-year, with both Battery & Energy Products and Communications Systems segments experiencing lower sales.
Gross profit margin fell to 21.3% from 25.1% year-over-year, impacted by unfavorable product mix, higher utility costs, and production disruptions.
Net loss attributable to shareholders was $0.5 million, or $(0.03) per share, compared to net income of $1.9 million, or $0.11 per share, in the prior year.
Adjusted EBITDA was $3.2 million (6.8% of sales), down from $5.4 million (10.7%) year-over-year.
Backlog reached a record $115.1 million, up 21.1% year-over-year, with over $12 million from new products released in the past year.
Financial highlights
Battery & Energy Products segment revenue was $44.2 million, down 4.7% year-over-year; medical sales increased 5.9%.
Communications Systems segment revenue was $3.3 million, down 25.7% year-over-year, mainly due to lower shipments to a major international defense contractor.
Consolidated gross profit was $10.1 million, down from $12.7 million year-over-year; gross margin declined to 21.3% from 25.1%.
Operating expenses rose to $10.3 million (21.8% of revenue), up 10.5% year-over-year, driven by higher R&D, consulting, litigation, and transition costs.
Cash at quarter-end was $8.9 million, down from $9.3 million at year-end 2025.
Outlook and guidance
Focused on improving manufacturing efficiency, Communications Systems revenue capture, gross margin in Battery & Energy Products, and vertical integration.
Expecting mid-year improvements from corrective actions on scrap and process enhancements.
Execution and replenishment of backlog expected to support cash flow, debt reduction, and strategic investments in 2026.
Continued investment in new product development and branding alignment to drive future growth.
Positive operating cash flow and available credit are expected to meet funding needs for the foreseeable future.
- Q4 revenue up 10.6% year-over-year; impairment led to net loss, but backlog and new products support 2026 growth.ULBI
Q4 202510 Mar 2026 - Q2 revenue up 13% to $48.6M, but margins and net income declined; outlook for H2 is positive.ULBI
Q2 20253 Feb 2026 - Record segment sales, margin gains, and major debt reduction highlight Q2 2024.ULBI
Q2 20243 Feb 2026 - Q3 revenue and profit declined, but debt reduction and a $50M acquisition set up future growth.ULBI
Q3 202415 Jan 2026 - Q4 revenue was $43.9M, with Electrochem acquisition and strong backlog driving 2025 growth.ULBI
Q4 202424 Dec 2025 - Director elections, auditor ratification, and governance updates highlight the 2025 proxy.ULBI
Proxy Filing1 Dec 2025 - Vote on director elections and auditor ratification at the July 16, 2025 annual meeting.ULBI
Proxy Filing1 Dec 2025 - Q1 2025 revenue up 21% to $50.7M, but net income and margins declined on higher costs.ULBI
Q1 202526 Nov 2025 - Q3 2025 revenue up 21.5% to $43.4M, but net loss of $1.22M on lower margins and one-time costs.ULBI
Q3 202519 Nov 2025
Next Ultralife earnings date
Next Ultralife earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)